Supplementary Material for: Pulse Corticosteroid Therapy for Alopecia Areata: Long-Term Outcome after 10 Years

<b><i>Background:</i></b> Few data are available concerning the efficiency of pulse corticosteroids in alopecia areata (AA).<b><i> Objective:</i></b> Our purpose was to assess the long-term outcomes of patients treated with methylprednisolone bolus. <b><i>Methods:</i></b> This study included 60 patients treated between 1995 and 2000. The short-term outcomes were analyzed in 2000. The long-term assessment of 30 patients was performed in 2010 by phone questionnaire. <b><i>Results:</i></b> Significant hair regrowth was observed in 10/30 patients at 6 months after the bolus treatment. Half of the plurifocalis AA patients were responders at 6 months, but less than one quarter of alopecia totalis (AT) and alopecia universalis (AU) patients responded. Long-term outcomes were assessed after a mean duration of 12.3 years; 8/10 initial responders had mild or no disease, and 14/20 initial nonresponders had severe AA. <b><i>Conclusions:</i></b> This study confirmed the low efficiency, both short- and long-term, of this treatment for AT and AU

Immunomodulatory or/and immunosuppressive drugs should not avoid skin test for the assessment of drug allergy

International audienceThe use of immunomodulatory and/or immunosuppressive therapy (IT) is increasingly common in the management of chronic inflammatory disease. Skin reactions to any drug (IT or not) are not rare in these patients, justifying allergological investigations. The influence of IT on allergological tests for drugs is not clearly described. IT cannot be interrupted due to the underlying disease. The data assessing the benefit and the safety of allergological test for drug allergy in patients under IT are missing